Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 1219 entries
Sorted by: Best Match Show Resources per page
A Prospective Pilot Clinical Trial to Evaluate the Efficacy and Safety of Topical Therapy with Ingenol Mebutate Gel 0.015% for Actinic Keratosis on an Expanded Area of the Chest.

The Journal of clinical and aesthetic dermatology

Wu DC, Guiha I, Goldman MP.
PMID: 28979661
J Clin Aesthet Dermatol. 2017 Aug;10(8):31-36. Epub 2017 Aug 01.

No abstract available.

Cite
Wu DC, Guiha I, Goldman MP. A Prospective Pilot Clinical Trial to Evaluate the Efficacy and Safety of Topical Therapy with Ingenol Mebutate Gel 0.015% for Actinic Keratosis on an Expanded Area of the Chest. J Clin Aesthet Dermatol. 2017;10(8):31-36
Wu, D. C., Guiha, I., & Goldman, M. P. (2017). A Prospective Pilot Clinical Trial to Evaluate the Efficacy and Safety of Topical Therapy with Ingenol Mebutate Gel 0.015% for Actinic Keratosis on an Expanded Area of the Chest. The Journal of clinical and aesthetic dermatology, 10(8), 31-36.
Wu, Douglas C, et al. "A Prospective Pilot Clinical Trial to Evaluate the Efficacy and Safety of Topical Therapy with Ingenol Mebutate Gel 0.015% for Actinic Keratosis on an Expanded Area of the Chest." The Journal of clinical and aesthetic dermatology vol. 10,8 (2017): 31-36.
Wu DC, Guiha I, Goldman MP. A Prospective Pilot Clinical Trial to Evaluate the Efficacy and Safety of Topical Therapy with Ingenol Mebutate Gel 0.015% for Actinic Keratosis on an Expanded Area of the Chest. J Clin Aesthet Dermatol. 2017 Aug;10(8):31-36. Epub 2017 Aug 01. PMID: 28979661; PMCID: PMC5605212.
Copy Download .nbib Format: NLM
Topical Treatment of Aging Hands: Brief Report.

The Journal of clinical and aesthetic dermatology

Roberts WE, Colvan L, Gotz V.
PMID: 28979662
J Clin Aesthet Dermatol. 2017 Aug;10(8):37-41. Epub 2017 Aug 01.

Rejuvenation of aging hands is becoming increasingly important to physicians and their patients. While a variety of invasive treatments are available, topical products that improve manifestations of aging hands are needed. In this brief report, the efficacy of a...

Cite
Roberts WE, Colvan L, Gotz V. Topical Treatment of Aging Hands: Brief Report. J Clin Aesthet Dermatol. 2017;10(8):37-41
Roberts, W. E., Colvan, L., & Gotz, V. (2017). Topical Treatment of Aging Hands: Brief Report. The Journal of clinical and aesthetic dermatology, 10(8), 37-41.
Roberts, Wendy E, et al. "Topical Treatment of Aging Hands: Brief Report." The Journal of clinical and aesthetic dermatology vol. 10,8 (2017): 37-41.
Roberts WE, Colvan L, Gotz V. Topical Treatment of Aging Hands: Brief Report. J Clin Aesthet Dermatol. 2017 Aug;10(8):37-41. Epub 2017 Aug 01. PMID: 28979662; PMCID: PMC5605213.
Copy Download .nbib Format: NLM
Molecular Insights into Fully Human and Humanized Monoclonal Antibodies: What are the Differences and Should Dermatologists Care?.

The Journal of clinical and aesthetic dermatology

Mallbris L, Davies J, Glasebrook A, Tang Y, Glaesner W, Nickoloff BJ.
PMID: 27672407
J Clin Aesthet Dermatol. 2016 Jul;9(7):13-5. Epub 2016 Jul 01.

In recent years, a large number of therapeutic monoclonal antibodies have come to market to treat a variety of conditions including patients with immune-mediated chronic inflammation. Distinguishing the relative clinical efficacy and safety profiles of one monoclonal antibody relative...

Cite
Mallbris L, Davies J, Glasebrook A, et al. Molecular Insights into Fully Human and Humanized Monoclonal Antibodies: What are the Differences and Should Dermatologists Care?. J Clin Aesthet Dermatol. 2016;9(7):13-5
Mallbris, L., Davies, J., Glasebrook, A., Tang, Y., Glaesner, W., & Nickoloff, B. J. (2016). Molecular Insights into Fully Human and Humanized Monoclonal Antibodies: What are the Differences and Should Dermatologists Care?. The Journal of clinical and aesthetic dermatology, 9(7), 13-5.
Mallbris, Lotus, et al. "Molecular Insights into Fully Human and Humanized Monoclonal Antibodies: What are the Differences and Should Dermatologists Care?." The Journal of clinical and aesthetic dermatology vol. 9,7 (2016): 13-5.
Mallbris L, Davies J, Glasebrook A, Tang Y, Glaesner W, Nickoloff BJ. Molecular Insights into Fully Human and Humanized Monoclonal Antibodies: What are the Differences and Should Dermatologists Care?. J Clin Aesthet Dermatol. 2016 Jul;9(7):13-5. Epub 2016 Jul 01. PMID: 27672407; PMCID: PMC5022998.
Copy Download .nbib Format: NLM
Improving Treatment of Erythematotelangiectatic Rosacea with Laser and/or Topical Therapy Through Enhanced Discrimination of its Clinical Features.

The Journal of clinical and aesthetic dermatology

Micali G, Gerber PA, Lacarrubba F, Schäfer G.
PMID: 27672409
J Clin Aesthet Dermatol. 2016 Jul;9(7):30-9. Epub 2016 Jul 01.

Rosacea is a chronic inflammatory disease that can present with a variety of cutaneous symptoms. Erythematotelangiectatic rosacea is a subtype characterized by flushing (transient erythema), persistent central facial erythema (background erythema), and telangiectasias. The severity of individual symptoms differs...

Cite
Micali G, Gerber PA, Lacarrubba F, et al. Improving Treatment of Erythematotelangiectatic Rosacea with Laser and/or Topical Therapy Through Enhanced Discrimination of its Clinical Features. J Clin Aesthet Dermatol. 2016;9(7):30-9
Micali, G., Gerber, P. A., Lacarrubba, F., & Schäfer, G. (2016). Improving Treatment of Erythematotelangiectatic Rosacea with Laser and/or Topical Therapy Through Enhanced Discrimination of its Clinical Features. The Journal of clinical and aesthetic dermatology, 9(7), 30-9.
Micali, Giuseppe, et al. "Improving Treatment of Erythematotelangiectatic Rosacea with Laser and/or Topical Therapy Through Enhanced Discrimination of its Clinical Features." The Journal of clinical and aesthetic dermatology vol. 9,7 (2016): 30-9.
Micali G, Gerber PA, Lacarrubba F, Schäfer G. Improving Treatment of Erythematotelangiectatic Rosacea with Laser and/or Topical Therapy Through Enhanced Discrimination of its Clinical Features. J Clin Aesthet Dermatol. 2016 Jul;9(7):30-9. Epub 2016 Jul 01. PMID: 27672409; PMCID: PMC5023001.
Copy Download .nbib Format: NLM
Long-term Multi-product Facial Regimen in Subjects with Moderate-to-severe Photodamage and Hyperpigmentation.

The Journal of clinical and aesthetic dermatology

Herndon JH, Makino ET, Jiang LI, Stephens TJ, Mehta RC.
PMID: 26345199
J Clin Aesthet Dermatol. 2015 Aug;8(8):16-21.

BACKGROUND: Photoaged skin is primarily a result of chronic sun exposure. Irregular pigmentation and wrinkling are common clinical manifestations. Monotherapy with retinoids, growth factors, and skin lighteners have proven beneficial. However, long-term treatment with a multi-product facial regimen has...

Cite
Herndon JH, Makino ET, Jiang LI, et al. Long-term Multi-product Facial Regimen in Subjects with Moderate-to-severe Photodamage and Hyperpigmentation. J Clin Aesthet Dermatol. 2015;8(8):16-21
Herndon, J. H., Makino, E. T., Jiang, L. I., Stephens, T. J., & Mehta, R. C. (2015). Long-term Multi-product Facial Regimen in Subjects with Moderate-to-severe Photodamage and Hyperpigmentation. The Journal of clinical and aesthetic dermatology, 8(8), 16-21.
Herndon, James H, et al. "Long-term Multi-product Facial Regimen in Subjects with Moderate-to-severe Photodamage and Hyperpigmentation." The Journal of clinical and aesthetic dermatology vol. 8,8 (2015): 16-21.
Herndon JH, Makino ET, Jiang LI, Stephens TJ, Mehta RC. Long-term Multi-product Facial Regimen in Subjects with Moderate-to-severe Photodamage and Hyperpigmentation. J Clin Aesthet Dermatol. 2015 Aug;8(8):16-21. PMID: 26345199; PMCID: PMC4557846.
Copy Download .nbib Format: NLM
Dermatological Adverse Events Associated with Topical Brimonidine Gel 0.33% in Subjects with Erythema of Rosacea: A Retrospective Review of Clinical Studies.

The Journal of clinical and aesthetic dermatology

Holmes AD, Waite KA, Chen MC, Palaniswamy K, Wiser TH, Draelos ZD, Rafal ES, Werschler WP, Harvey AE.
PMID: 26345379
J Clin Aesthet Dermatol. 2015 Aug;8(8):29-35.

BACKGROUND: The topical α2 adrenergic receptor agonist brimonidine gel 0.33% is an effective and safe pharmacological treatment for the facial erythema of rosacea. However, adverse events of worsened redness have occasionally been reported with its use.OBJECTIVE: A detailed analysis...

Cite
Holmes AD, Waite KA, Chen MC, et al. Dermatological Adverse Events Associated with Topical Brimonidine Gel 0.33% in Subjects with Erythema of Rosacea: A Retrospective Review of Clinical Studies. J Clin Aesthet Dermatol. 2015;8(8):29-35
Holmes, A. D., Waite, K. A., Chen, M. C., Palaniswamy, K., Wiser, T. H., Draelos, Z. D., Rafal, E. S., Werschler, W. P., & Harvey, A. E. (2015). Dermatological Adverse Events Associated with Topical Brimonidine Gel 0.33% in Subjects with Erythema of Rosacea: A Retrospective Review of Clinical Studies. The Journal of clinical and aesthetic dermatology, 8(8), 29-35.
Holmes, Anna D, et al. "Dermatological Adverse Events Associated with Topical Brimonidine Gel 0.33% in Subjects with Erythema of Rosacea: A Retrospective Review of Clinical Studies." The Journal of clinical and aesthetic dermatology vol. 8,8 (2015): 29-35.
Holmes AD, Waite KA, Chen MC, Palaniswamy K, Wiser TH, Draelos ZD, Rafal ES, Werschler WP, Harvey AE. Dermatological Adverse Events Associated with Topical Brimonidine Gel 0.33% in Subjects with Erythema of Rosacea: A Retrospective Review of Clinical Studies. J Clin Aesthet Dermatol. 2015 Aug;8(8):29-35. PMID: 26345379; PMCID: PMC4557848.
Copy Download .nbib Format: NLM
Idiopathic Flushing with Dysesthesia: Treatment with the 585nm Pulsed Dye Laser.

The Journal of clinical and aesthetic dermatology

Fogelman JP, Stevenson ML, Ashinoff R, Soter NA.
PMID: 26345489
J Clin Aesthet Dermatol. 2015 Aug;8(8):36-41.

OBJECTIVE: The purpose of this study was to analyze the efficacy and safety of the 585nm pulsed dye laser for the treatment of idiopathic flushing with dysesthesia.DESIGN: This was a retrospective study of patients treated with a 585nm pulsed...

Cite
Fogelman JP, Stevenson ML, Ashinoff R, et al. Idiopathic Flushing with Dysesthesia: Treatment with the 585nm Pulsed Dye Laser. J Clin Aesthet Dermatol. 2015;8(8):36-41
Fogelman, J. P., Stevenson, M. L., Ashinoff, R., & Soter, N. A. (2015). Idiopathic Flushing with Dysesthesia: Treatment with the 585nm Pulsed Dye Laser. The Journal of clinical and aesthetic dermatology, 8(8), 36-41.
Fogelman, Joshua P, et al. "Idiopathic Flushing with Dysesthesia: Treatment with the 585nm Pulsed Dye Laser." The Journal of clinical and aesthetic dermatology vol. 8,8 (2015): 36-41.
Fogelman JP, Stevenson ML, Ashinoff R, Soter NA. Idiopathic Flushing with Dysesthesia: Treatment with the 585nm Pulsed Dye Laser. J Clin Aesthet Dermatol. 2015 Aug;8(8):36-41. PMID: 26345489; PMCID: PMC4557849.
Copy Download .nbib Format: NLM
Q-Switched Alexandrite Laser-induced Chrysiasis.

The Journal of clinical and aesthetic dermatology

Cohen PR, Ross EV.
PMID: 26430491
J Clin Aesthet Dermatol. 2015 Sep;8(9):48-53.

BACKGROUND: Chyriasis is an uncommon side effect that occurs in patients who are receiving prolonged treatment with either intravenous or intramuscular gold as a distinctive blue-gray pigmentation of light-exposed skin. Laser-induced chrysiasis is a rarely described phenomenon in individuals...

Cite
Cohen PR, Ross EV. Q-Switched Alexandrite Laser-induced Chrysiasis. J Clin Aesthet Dermatol. 2015;8(9):48-53
Cohen, P. R., & Ross, E. V. (2015). Q-Switched Alexandrite Laser-induced Chrysiasis. The Journal of clinical and aesthetic dermatology, 8(9), 48-53.
Cohen, Philip R, and Ross, E Victor. "Q-Switched Alexandrite Laser-induced Chrysiasis." The Journal of clinical and aesthetic dermatology vol. 8,9 (2015): 48-53.
Cohen PR, Ross EV. Q-Switched Alexandrite Laser-induced Chrysiasis. J Clin Aesthet Dermatol. 2015 Sep;8(9):48-53. PMID: 26430491; PMCID: PMC4587895.
Copy Download .nbib Format: NLM
The Benefit of Dual-frequency Ultrasound in Patients Treated by Injection Lipolysis.

The Journal of clinical and aesthetic dermatology

Tausch I, Kruglikov I.
PMID: 26345611
J Clin Aesthet Dermatol. 2015 Aug;8(8):42-6.

OBJECTIVE: To assess whether dual-frequency ultrasound can improve the treatment results of injection lipolysis (IL).DESIGN: Randomized, single-center pilot study. All subjects were treated with a contralateral control: one side of the body received the treatment with IL, whereas the...

Cite
Tausch I, Kruglikov I. The Benefit of Dual-frequency Ultrasound in Patients Treated by Injection Lipolysis. J Clin Aesthet Dermatol. 2015;8(8):42-6
Tausch, I., & Kruglikov, I. (2015). The Benefit of Dual-frequency Ultrasound in Patients Treated by Injection Lipolysis. The Journal of clinical and aesthetic dermatology, 8(8), 42-6.
Tausch, Irene, and Kruglikov, Ilja. "The Benefit of Dual-frequency Ultrasound in Patients Treated by Injection Lipolysis." The Journal of clinical and aesthetic dermatology vol. 8,8 (2015): 42-6.
Tausch I, Kruglikov I. The Benefit of Dual-frequency Ultrasound in Patients Treated by Injection Lipolysis. J Clin Aesthet Dermatol. 2015 Aug;8(8):42-6. PMID: 26345611; PMCID: PMC4557850.
Copy Download .nbib Format: NLM
Drug-induced Telogen Effluvium in a Pediatric Patient due to Error of Transcription.

The Journal of clinical and aesthetic dermatology

Feldstein S, Awasthi S, Krakowski AC.
PMID: 26346096
J Clin Aesthet Dermatol. 2015 Aug;8(8):52-4.

"Errors of transcription" are rarely reported, but may cause significant adverse effects in patients. Here, the authors report the case of a 15-year-old Burmese girl presenting with telogen effluvium after being dispensed the wrong medication due to a pharmacy...

Cite
Feldstein S, Awasthi S, Krakowski AC. Drug-induced Telogen Effluvium in a Pediatric Patient due to Error of Transcription. J Clin Aesthet Dermatol. 2015;8(8):52-4
Feldstein, S., Awasthi, S., & Krakowski, A. C. (2015). Drug-induced Telogen Effluvium in a Pediatric Patient due to Error of Transcription. The Journal of clinical and aesthetic dermatology, 8(8), 52-4.
Feldstein, Stephanie, et al. "Drug-induced Telogen Effluvium in a Pediatric Patient due to Error of Transcription." The Journal of clinical and aesthetic dermatology vol. 8,8 (2015): 52-4.
Feldstein S, Awasthi S, Krakowski AC. Drug-induced Telogen Effluvium in a Pediatric Patient due to Error of Transcription. J Clin Aesthet Dermatol. 2015 Aug;8(8):52-4. PMID: 26346096; PMCID: PMC4557852.
Copy Download .nbib Format: NLM
FOCUS ON PSORIASIS: A REPORT FROM THE 73RD ANNUAL MEETING OF THE AMERICAN ACADEMY OF DERMATOLOGYPsoriasis-related topics included targeted therapies, safety of biologies, comorbidities.

The Journal of clinical and aesthetic dermatology

Donigan JM.
PMID: 26240675
J Clin Aesthet Dermatol. 2015 Jul;8(7):8-16.

No abstract available.

Cite
Donigan JM. FOCUS ON PSORIASIS: A REPORT FROM THE 73RD ANNUAL MEETING OF THE AMERICAN ACADEMY OF DERMATOLOGYPsoriasis-related topics included targeted therapies, safety of biologies, comorbidities. J Clin Aesthet Dermatol. 2015;8(7):8-16
Donigan, J. M. (2015). FOCUS ON PSORIASIS: A REPORT FROM THE 73RD ANNUAL MEETING OF THE AMERICAN ACADEMY OF DERMATOLOGYPsoriasis-related topics included targeted therapies, safety of biologies, comorbidities. The Journal of clinical and aesthetic dermatology, 8(7), 8-16.
Donigan, Jessica M. "FOCUS ON PSORIASIS: A REPORT FROM THE 73RD ANNUAL MEETING OF THE AMERICAN ACADEMY OF DERMATOLOGYPsoriasis-related topics included targeted therapies, safety of biologies, comorbidities." The Journal of clinical and aesthetic dermatology vol. 8,7 (2015): 8-16.
Donigan JM. FOCUS ON PSORIASIS: A REPORT FROM THE 73RD ANNUAL MEETING OF THE AMERICAN ACADEMY OF DERMATOLOGYPsoriasis-related topics included targeted therapies, safety of biologies, comorbidities. J Clin Aesthet Dermatol. 2015 Jul;8(7):8-16. PMID: 26240675; PMCID: PMC4521138.
Copy Download .nbib Format: NLM
Topical Ivermectin: Data Supporting Dual Modes of Action in Rosacea.

The Journal of clinical and aesthetic dermatology

Del Rosso JQ.
PMID: 29515751
J Clin Aesthet Dermatol. 2017 Sep;10(9):39-42. Epub 2017 Sep 01.

Until recently, the potential modes of action of topical ivermectin in rosacea have been speculated but not studied. Short-term studies (12 week), long-term studies (up to 52 weeks), and case report series have now been completed, and topical ivermectin...

Cite
Del Rosso JQ. Topical Ivermectin: Data Supporting Dual Modes of Action in Rosacea. J Clin Aesthet Dermatol. 2017;10(9):39-42
Del Rosso, J. Q. (2017). Topical Ivermectin: Data Supporting Dual Modes of Action in Rosacea. The Journal of clinical and aesthetic dermatology, 10(9), 39-42.
Del Rosso, James Q. "Topical Ivermectin: Data Supporting Dual Modes of Action in Rosacea." The Journal of clinical and aesthetic dermatology vol. 10,9 (2017): 39-42.
Del Rosso JQ. Topical Ivermectin: Data Supporting Dual Modes of Action in Rosacea. J Clin Aesthet Dermatol. 2017 Sep;10(9):39-42. Epub 2017 Sep 01. PMID: 29515751; PMCID: PMC5749619.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 1219 entries